Cumberland Pharmaceuticals (CPIX) Reports Q1 EPS of $0.09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Cumberland Pharmaceuticals Reports First Quarter 2015 Financial Results
May 7, 2015 4:05 PM EDTNASHVILLE, Tenn., May 7, 2015 /PRNewswire/ --Â Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2015 financial results with Adjusted Earnings up 72% to $1.6 million or $0.09 per share. Net revenues were $8.7 million, compared to $8.1 million for the prior year period.
As of March 31, 2015 the Company had $53 million in cash and investments, approximately $92 million in total assets, and no debt. Cumberland also had $44 million in tax net operating loss carryforwards, resulting from the... More
